Rockville, MD, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The global autogenous vaccine for aquaculture market has been estimated at US$ 14.1 million in 2024 and is projected to reach a value of US$ 23.7 million by the end of 2034, as per a new study published by Fact.MR, a market research and competitive intelligence provider.
Evolving challenges in aquaculture are projected to increase demand for autogenous vaccines. Further, these vaccines provide customized solutions, therefore allowing producers of aquaculture to address particulate pathogen-related issues. In addition, growing awareness among aquaculture producers about the adoption of autogenous vaccines as a biosecurity measure is also contributing to market growth.
Increasing concerns about reducing the use of antibiotics and issues related to antibiotic resistance are driving demand for effective strategies for disease management. Furthermore, autogenous vaccines for aquaculture offer a non-antibiotic option to prevent and control diseases in aquatic species. Global demand for autogenous vaccines for aquaculture is noticed more in the farming of some high-value species, including trout, shrimp, and salmon.
For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=9754
Key Takeaways from Market Study
- The global autogenous vaccine for aquaculture market is projected to reach US$ 23.7 million by the end of 2034, expanding at a CAGR of 3% from 2024 to 2034.
- North America is projected to account for 25% share of global market revenue by 2034.
- Salmon species are forecasted to hold 4% share of the autogenous vaccine for aquaculture market by 2034-end.
- Sales of autogenous vaccines for aquaculture in Chile are projected to rise at a CAGR of 5% from 2024 to 2034.
“Increased emphasis on biosecurity, desire to minimize the use of antibiotics, and vaccine customization options are contributing to the rising demand for autogenous vaccines for aquaculture,” says a Fact.MR analyst.
Leading Players Driving Innovation in the Autogenous Vaccine for Aquaculture Market:
AniCon Labor GmbH, IDT Biologika GmbH, Zoetis, Vaccinova, HIPRA, MARINNOVAC, Barramundi Asia Pte Ltd., Sanphar (ipeve), and Kennebec River Biosciences are prominent suppliers of autogenous vaccines for aquaculture. They are investing significantly in new product development and innovation to gain a competitive edge in the market.
Rising Production of Salmon in Chile Driving Demand for Autogenous Vaccines:
Demand for autogenous vaccines for aquaculture in Chile is forecasted to increase at a CAGR of 4.5% and reach a market value of US$ 1.12 million by 2034-end. Growing production as well as export of salmon in the country has led to an inclination toward sustainability. Chile developed sustainable aquaculture practices for salmon, which can be further used for in human food and other purposes. In addition, increasing emphasis on minimizing the use of antibiotics is also fueling sales of autogenous vaccines for aquaculture in the country.
Autogenous Vaccine for Aquaculture Industry News:
Market players are prioritizing strategic acquisitions to harness innovative ideas and drive advancements. Partnerships are also being formed to enhance supply chain management systems. Leading manufacturers are actively addressing the needs of sustainable aquaculture farming by developing and producing practical and effective autogenous vaccines for aquaculture.
For example, TransAlgae is set to revolutionize aquaculture vaccination with the introduction of microalgae-based oral delivery technology in January 2021. In collaboration with Virbac, TransAlgae is leveraging its cutting-edge technology to develop a novel vaccine for aquaculture applications.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9754
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the autogenous vaccine for aquaculture market, presenting historical demand data for 2018 to 2023 and forecast statistics for 2024 to 2034.
The study divulges essential insights into the market based on fish species (salmon, tilapia, bream, labris bergylta, cyprinus carpio, sea bass, cyclopterus lumpus, trout), pathogen type (bacteria, virus), and end user (fish farming companies, aquatic research institutes), across six major regions of the world (North America, Europe, East Asia, Latin America, South Asia & Oceania, and MEA).
Check out More Related Studies Published by Fact.MR Research:
Commercial aquaculture vaccine market size has been calculated at US$ 305.2 million for 2024 and is projected to expand at a CAGR of 6.7% and reach a size of US$ 584.3 million by 2034-end.
Aquaculture feed and pharmaceutical market is valued at US$ 999.4 million in 2024 and is projected to grow at a CAGR of 7.4%, reaching US$ 2.04 billion by 2034.
Autogenous vaccine market is estimated at US$ 144.8 million in 2024 and is projected to grow at a 5.5% CAGR, reaching US$ 246.8 million by 2034.
Vaccine delivery systems market is projected to reach US$ 4.14 billion by the end of 2022 and is expected to grow at a CAGR of 9.5%, reaching US$ 10.25 billion by 2032 during the 2022–2032 assessment period.
Animal vaccine market is valued at US$ 15.62 billion in 2024 and is projected to grow at a CAGR of 9.1%, reaching US$ 37.42 billion by 2034.
About Us:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team : sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
